Regeneron Pharmaceuticals Inc (REGN)vsTG Therapeutics Inc (TGTX)
REGN
Regeneron Pharmaceuticals Inc
$749.47
+1.05%
HEALTHCARE · Cap: $78.41B
TGTX
TG Therapeutics Inc
$31.82
+5.29%
HEALTHCARE · Cap: $4.83B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 2227% more annual revenue ($14.34B vs $616.29M). TGTX leads profitability with a 72.6% profit margin vs 31.4%. REGN appears more attractively valued with a PEG of 1.56. TGTX earns a higher WallStSmart Score of 63/100 (C+).
REGN
Buy58
out of 100
Grade: C
TGTX
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-165.8%
Fair Value
$281.93
Current Price
$749.47
$467.54 premium
Margin of Safety
-53.0%
Fair Value
$18.84
Current Price
$31.82
$12.98 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Safe zone — low bankruptcy risk
Large-cap with strong market position
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 23.1%
Attractively priced relative to earnings
Every $100 of equity generates 103 in profit
Keeps 73 of every $100 in revenue as profit
Revenue surging 78.0% year-over-year
Strong operational efficiency at 26.2%
Areas to Watch
Expensive relative to growth rate
2.5% revenue growth
Weak financial health signals
Earnings declined 2.6%
Expensive relative to growth rate
Earnings declined 6.1%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : REGN
The strongest argument for REGN centers on Profit Margin, Altman Z-Score, Market Cap. Profitability is solid with margins at 31.4% and operating margin at 23.1%.
Bull Case : TGTX
The strongest argument for TGTX centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 72.6% and operating margin at 26.2%. Revenue growth of 78.0% demonstrates continued momentum.
Bear Case : REGN
The primary concerns for REGN are PEG Ratio, Revenue Growth, Piotroski F-Score.
Bear Case : TGTX
The primary concerns for TGTX are PEG Ratio, EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
REGN profiles as a value stock while TGTX is a growth play — different risk/reward profiles.
TGTX carries more volatility with a beta of 1.86 — expect wider price swings.
TGTX is growing revenue faster at 78.0% — sustainability is the question.
REGN generates stronger free cash flow (922M), providing more financial flexibility.
Bottom Line
TGTX scores higher overall (63/100 vs 58/100), backed by strong 72.6% margins and 78.0% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
TG Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in New York, New York.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?